Technology
This technology is based on the identification of the deubiquitinase CYLD as a key contributor to autism spectrum disorder (ASD)-like traits and related neuropsychiatric changes.
The underlying concept is that reduced CYLD activity is linked to behavioral, synaptic, morphological, and molecular alterations associated with ASD, making CYLD relevant both as a biomarker and as a therapeutic target.
Loss of CYLD was associated with impaired synaptic transmission in the CA1 region of the hippocampus, reduced dendrite length, and a lower number of dendritic spines, indicating a mechanistic link between CYLD function and neuronal connectivity.
Based on these findings, the technology enables a dual approach: diagnostic use through detection of decreased CYLD levels and therapeutic development through agents designed to increase CYLD activity.
